Bryan Ball Sells 6,596 Shares of Whitehawk Therapeutics (NASDAQ:WHWK) Stock

Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) insider Bryan Ball sold 6,596 shares of the business’s stock in a transaction dated Friday, April 10th. The shares were sold at an average price of $3.43, for a total value of $22,624.28. Following the transaction, the insider owned 515,955 shares in the company, valued at approximately $1,769,725.65. This represents a 1.26% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Bryan Ball also recently made the following trade(s):

• On Thursday, April 9th, Bryan Ball sold 50,000 shares of Whitehawk Therapeutics stock. The shares were sold at an average price of $3.57, for a total value of $178,500.00.
• On Monday, March 2nd, Bryan Ball sold 1,834 shares of Whitehawk Therapeutics stock. The shares were sold at an average price of $3.31, for a total value of $6,070.54.

Whitehawk Therapeutics Price Performance

NASDAQ:WHWK traded up $0.08 during mid-day trading on Monday, reaching $3.47. 143,959 shares of the company’s stock traded hands, compared to its average volume of 178,839. Whitehawk Therapeutics, Inc. has a 12-month low of $1.39 and a 12-month high of $4.48. The firm has a market capitalization of $163.78 million, a price-to-earnings ratio of 7.38 and a beta of 0.57. The company has a 50 day moving average price of $3.36 and a 200-day moving average price of $2.73.

Whitehawk Therapeutics (NASDAQ:WHWK) last announced its quarterly earnings results on Thursday, March 12th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.55) by $0.21.

Analyst Upgrades and Downgrades

Several analysts have weighed in on WHWK shares. Oppenheimer started coverage on Whitehawk Therapeutics in a research report on Thursday, February 5th. They set an “outperform” rating and a $6.00 price objective on the stock. JonesTrading started coverage on Whitehawk Therapeutics in a research report on Monday, December 22nd. They set a “buy” rating and a $7.00 price objective on the stock. Wall Street Zen cut Whitehawk Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Whitehawk Therapeutics in a research report on Friday, March 27th. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Whitehawk Therapeutics has a consensus rating of “Hold” and a consensus target price of $6.50.

Institutional Trading of Whitehawk Therapeutics

Hedge funds have recently made changes to their positions in the stock. Quadrature Capital Ltd bought a new stake in shares of Whitehawk Therapeutics in the 4th quarter worth approximately $28,000. ABG Innovation Capital Partners III GP Ltd bought a new position in Whitehawk Therapeutics in the 3rd quarter valued at approximately $51,000. Dimensional Fund Advisors LP bought a new position in Whitehawk Therapeutics in the 3rd quarter valued at approximately $84,000. Squarepoint Ops LLC bought a new position in Whitehawk Therapeutics in the 3rd quarter valued at approximately $159,000. Finally, Marshall Wace LLP bought a new position in Whitehawk Therapeutics in the 4th quarter valued at approximately $164,000. 52.08% of the stock is owned by institutional investors.

About Whitehawk Therapeutics

Aadi Bioscience, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.